Health Care·Pharmaceuticals·$4.6B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-0.01 | N/A | +85.71% |
| Revenue | N/A | N/A | N/A |
management commentary, guidance changes, and full analysis available with Pro.
| EPS | $-0.01 | N/A | +85.71% |
| Revenue | N/A | N/A | N/A |
Tone: Cautiously Optimistic
Management seemed pleased with the earnings surprise on EPS. However, they did not provide detailed insights into revenue or future guidance.
Management expressed satisfaction with the EPS performance despite not providing revenue figures.
They highlighted ongoing projects and potential future developments.
Ligand Pharmaceuticals reported a smaller-than-expected loss per share, which led to a positive stock reaction, rising 6.43%. The earnings surprise indicates better-than-anticipated cost management or operational efficiency. However, the lack of revenue data and guidance leaves some uncertainty about future performance.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
NRG ENERGY INC
Nov 2, 2012